BioCentury
ARTICLE | Preclinical News

Rosenberg study highlights opportunity for blood-based take on TILs against mutant p53

A study from TIL pioneer Rosenberg supports a path for therapies based on peripheral T cells

January 29, 2020 10:13 AM UTC
Updated on Feb 1, 2020 at 6:43 PM UTC

A new study from TIL pioneer Steve Rosenberg adds to the momentum of blood-derived personalized T cell therapies by showing concordance between T cell responses against common p53 mutations in patients’ solid tumors and those in their circulation.

Clinical studies led by NCI Chief of Surgery Steven Rosenberg have shown that isolating, expanding and re-infusing autologous tumor infiltrating lymphocytes (TILs) specific for cancer neoantigens can elicit durable responses against metastatic solid tumors. ...

BCIQ Company Profiles

National Cancer Institute

BCIQ Target Profiles

p53 (TP53)